Editor’s Note
**Editor’s Note:** The FDA has approved Obagi Saypha ChIQ, a hyaluronic acid injectable for cheek augmentation, expanding Obagi Medical’s aesthetic portfolio under its alliance with Croma-Pharma. This follows last September’s approval of Saypha MagIQ, marking the company’s continued push into the injectables market.
The U.S. Food and Drug Administration (FDA) has approved Obagi Saypha ChIQ, expanding Obagi Medical’s portfolio of minimally invasive aesthetic products under its strategic commercial alliance with Croma-Pharma. The new hyaluronic acid injectable is indicated for cheek augmentation and correction of defects in the midface contour.
Last September, Obagi Medical, owned by British private equity firm Bridgepoint Group, entered the aesthetic injectables market with FDA approval of Saypha MagIQ. The launch of its hyaluronic acid filler for moderate to severe nasolabial folds positioned it in direct competition with established filler lines such as RHA from Switzerland’s Teoxane, Restylane from fellow Swiss company Galderma, and Juvéderm from U.S.-based Allergan (AbbVie).
Now, the company expands its portfolio with FDA approval of Obagi Saypha ChIQ, a hyaluronic acid filler designed for cheek augmentation and correction of midface contour defects in patients aged 21 and older.
Like MagIQ, ChIQ results from a collaboration with Austria-based Croma-Pharma, which has decades of experience in the injectable filler sector. The foundation of ChIQ is its MACRO Core technology, a specialized hyaluronic acid matrix designed to provide a filler more suitable for defining shape, contour, and projection of the cheeks and midface area.
